Proactive Investors - Run By Investors For Investors

Canntab Therapeutics inks pact with Heritage Cannabis for processing hemp for CBD-filled gelcaps

Heritage's subsidiary Purefarma Solutions will take hemp from Canntab for the purpose of processing it into high-quality CBD oil
CBD gelcaps
Canntab is best known for its tablet technology, which includes an extended-release, instant-release, flash melt tablet and more

Canntab Therapeutics Limited (CSE:PILL.CN) (OTCMKTS:CTABF) said Thursday that it has inked a pact with Heritage Cannabis Holdings Corp (CSE:CANN)(OTCQX:HERTF) for processing hemp for sale of CBD filled gel capsules.

Canntab has a Health Canada license to cultivate industrial hemp that it uses to extract cannabidiol (CBD) to manufacture cannabis pills.

According to the term sheet, Canntab will provide hemp to Heritage's subsidiary Purefarma Solutions for the purpose of processing that hemp into high quality CBD oil.

READ: Canntab Therapeutics fills a gap with its pioneering cannabis oral dosage products

The oil will then be turned into capsules by Canntab for Heritage, FSD Pharma Inc (CSE:HUGE), and other white labelling opportunities.

The agreement will begin immediately and is open-ended, non-exclusive and subject to a 120-day cancellation notice by either party.

Strategic deal to spur growth 

“This agreement with Canntab is a strategic fit for our growth as a contract service provider. It aligns with our vision to operate in final product verticals and advances our offering in the medical cannabis sector,” said Heritage Cannabis Holdings CEO Clint Sharples. “Purefarma’s extraction expertise and ability to provide quality oil is a good match for the high expectations that Canntab has for the products they will be bringing to market.”

Canntab's oral delivery system treats different ailments by delivering a uniform dosage of medicinal cannabis extract.

"After recently announcing the receipt of our cultivation licence for industrial hemp from Health Canada, we are immediately entering into important agreements to generate both short term and sustained revenue for the company,” said Canntab co-founder and CEO Jeff Renwick. “Our ability to encapsulate allows us to generate revenue without losing our long term focus on becoming the leading supplier of hard pill oral dose cannabinoid and terpene blends in the world."

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full PILL profile View Profile

Canntab Therapeutics Ltd Timeline

Related Articles

Strainsecure platform
June 19 2019
The company’s blockchain-based platform is designed to guarantee product quality and genetics throughout the cannabis supply chain from genome to patient
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
cannabis
June 08 2019
1933 Industries is progressing with plans to launch one of Nevada's largest hemp extraction facilities, amid a flurry of other activity
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use